Axsome Therapeutics (AXSM, Financial) receives continual support from HC Wainwright & Co., as the investment firm reiterates its Buy rating on the stock. The most recent analysis conducted by Raghuram Selvaraju was released on June 10, 2025, emphasizing the company's potential in the therapeutic sector.
The price target set by HC Wainwright & Co. remains unchanged at $180.00, reflecting a confident outlook in Axsome Therapeutics' (AXSM, Financial) future performance. This target is consistent with the prior expectation from the firm, signaling a stable view on the stock's valuation potential.
Investors in Axsome Therapeutics (AXSM, Financial) can observe that the analyst's maintained rating and price target are aligned with the sustained buy recommendation, indicating continuous trust in the company's capabilities to meet strategic goals and deliver value.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 18 analysts, the average target price for Axsome Therapeutics Inc (AXSM, Financial) is $176.17 with a high estimate of $210.00 and a low estimate of $146.00. The average target implies an upside of 60.34% from the current price of $109.87. More detailed estimate data can be found on the Axsome Therapeutics Inc (AXSM) Forecast page.
Based on the consensus recommendation from 19 brokerage firms, Axsome Therapeutics Inc's (AXSM, Financial) average brokerage recommendation is currently 1.6, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Axsome Therapeutics Inc (AXSM, Financial) in one year is $259.61, suggesting a upside of 136.29% from the current price of $109.87. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Axsome Therapeutics Inc (AXSM) Summary page.
